If You Invested $5,000 in Vaxart During the Last Recession, This Is How Much You Would Have Today
Vaxart (NASDAQ: VXRT), the San Francisco-area clinical-stage biotech company, has made and lost millions for investors this year.
On Feb. 3, at the beginning of the recession, Vaxart's shares opened at $1.32 a share, buoyed by a Jan. 31 announcement that it had started a program to develop an oral vaccine to fight the coronavirus.
By July, the stock was up to $17.49. Those who had spent $5,000 on the stock when it was at $1.32 would have received 3,787 shares at the time, assuming they didn't buy any split shares. If they sold the stock at its 52-week peak, their investment would have left them with $66,235, including a net profit of $61,236.
Source Fool.com
